Ketamine Research and Policy Updates
News and research summaries focused on what changes in evidence, regulation, access, and clinical practice may mean for ketamine patients and providers.
What belongs here
Current research, policy, FDA, DEA, trial, and access updates with patient-facing context and links to primary sources when available.
What to read next
Use news articles for context, then move to the evergreen guide or safety hub for durable treatment planning information.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.
Featured
3 articlesExpert Highlights Critical Ketamine Patient Considerations
Dr. Benjamin Brody discusses essential patient considerations for ketamine therapy at major psychiatric conference, covering safety protocols and clinical best practices.
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects
Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.
Boston Ketamine Clinics: A Window Into Real-World Use
CBS News spotlights Boston ketamine clinics treating mental health conditions. What real-world patient outcomes reveal about low-dose ketamine therapy.
Expert Highlights Critical Ketamine Patient Considerations
Dr. Benjamin Brody discusses essential patient considerations for ketamine therapy at major psychiatric conference, covering safety protocols and clinical best practices.
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects
Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.
Boston Ketamine Clinics: A Window Into Real-World Use
CBS News spotlights Boston ketamine clinics treating mental health conditions. What real-world patient outcomes reveal about low-dose ketamine therapy.
What a Year of Experimental Depression Treatment Reveals
A Guardian journalist spent a year testing ketamine, TMS, and gut therapy for depression. Here's what their experience reveals about low-dose ketamine.
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial shows 16 weeks of CBT after esketamine significantly reduces relapse risk and suicidal ideation. What it means for ketamine patients.
Esketamine Safety Protocols: What Clinicians Now Emphasize
A new clinical overview on esketamine nasal spray details REMS requirements, two-hour monitoring, and vitals tracking. Here's what it means for ketamine patients.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy—and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
What Dropout Rates Reveal About NMDA Therapy Tolerability
New psychiatric guidance examines why patients stop NMDA antagonist therapy and what side effect data means for low-dose ketamine treatment decisions.
When Ketamine Side Effects Signal Time to Adjust Dose
New clinical analysis examines why patients stop NMDA antagonist therapy—and how smarter dose management may improve remission outcomes in TRD.
Faster TRD Remission Hinges on Measurement and Dose Timing
New analysis in Psychiatric Times shows that symptom tracking and rapid dose adjustment drive faster remission in TRD—here's what it means for ketamine care.
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
NMDA Antagonist Side Effects: What the Data Says
New clinical analysis examines why patients stop ketamine and esketamine treatment—and what smarter monitoring can do to keep them on track.
NRx FDA Review: Preservative-Free Ketamine Moves Forward
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what the formulation difference means for low-dose patients.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.
NRx Moves Closer to FDA-Approved Preservative-Free Ketamine
NRx Pharmaceuticals signals FDA review progress on its preservative-free ketamine application. What this means for patients and clinicians in 2026.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.
Psychedelics Executive Order: What It Means for Ketamine
A new executive order targets psychedelic medicine access. Here's what the policy shift means for low-dose ketamine patients and providers in 2026.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Insurance Gaps in Ketamine Care — And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
TRD Experts Push for Remission, Not Just Response
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for ketamine patients and their treatment plans.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
Clinicians are pushing beyond symptom reduction in treatment-resistant depression, aiming for full remission. Here's what that means for ketamine patients.